CB Scientific, Inc. has developed a novel product medical device portfolio since acquiring Marutronics Medical Devices in February 2017. The company has developed three core platform technologies; CannaRAPID, CannaNASAL, and CannaDERME, focused on precise dosing and controlled release of cannabinoid compounds for patients. CB Scientific has been developing Pain-Patch using CannaDERME transdermal delivery and smart device technologies for relieving various pains. CB Scientific has formulated cannabidiol-based Pain-Patch for proof-of-concept studies. Cannabidiol is one of the key cannabinoid constituents in Hemp Plant. CBD is non-psychoactive and safe compound with a wide range of therapeutic applications, including the treatment of neural disorders and clinical studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions. The Pain-Patch has transcutaneous cannabinoid penetration technology coupled with thermosensitive nano-emulsion for sustained release of compounds for longer time. The device delivers therapeutic doses to brain via brain stem for whole-body effect. The goal of these patches are to produce a pain-patch with a small footprint for easy concealment, a strong formula to counteract the decreased quality of life for individuals who suffer with systemic pain, a long shelf-life and the use of non-toxic and non-abrasive components to create the most comfortable and effective patch on the market using this technology. CB Scientific is partnering up with pain management physician groups for conducting clinical studies using Pain-Patch for various kinds of chronic pain. The first version of the pain patch should be available in the first quarter of 2017 (fiscal year) through authorized dealers.